- COSCIENS Biopharma (CSCI, Financial) announces a major board reconstitution, appointing Peter H. Puccetti as Chair.
- Goodwood Inc. commits its 8.2% stake to support the new board structure.
- New board boasts industry veterans from the pharma and healthcare sectors, enhancing governance and shareholder value.
COSCIENS Biopharma Inc. (CSCI) has announced a significant restructuring of its board of directors through a Resolution Agreement with Goodwood Inc., Goodwood Fund, and Puccetti Funds Management. The reconstituted board, now composed of six seasoned directors, will be chaired by Peter H. Puccetti. This strategic move is designed to enhance corporate governance and maximize shareholder value.
The extensive backgrounds of the newly appointed directors bring a wealth of experience to COSCIENS. Among them are Anthony Giovinazzo, former CEO of Cynapsus Therapeutics, who led the company through a highly successful $841 million acquisition, and Ronald W. Miller, former CEO of Roche Canada, who has vast knowledge in pharmaceutical growth and innovation.
The agreement ensures Goodwood's commitment to vote its 8.2% ownership, which equals 257,257 shares, in favor of the new board members during the rescheduled 2025 Annual Meeting on June 30, 2025. This support aims to provide stability and align interests with COSCIENS’ future objectives.
In addition to restructuring the board, the formation of new Audit and Human Resources committees indicates a reinforced focus on improving governance. The Reconstituted Board is set to actively review company prospects, signaling potential strategic shifts to explore opportunities and enhance market position.
COSCIENS thanks outgoing directors for their contributions, as the newly appointed team looks forward to crafting a robust future for shareholders with fresh strategies and insights.
